CELC · XBRL financial data

Celcuity financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CELC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	7,684	25,758	35,290	60,594	104,203	144,995
General and administrative	1,873	2,598	4,102	5,636	9,064	27,197
Total operating expenses	9,556	28,356	39,391	66,230	113,267	172,192
Operating income (loss)	(9,556)	(28,356)	(39,391)	(66,230)	(113,267)	(172,192)
Interest income	82	13	1,127	7,778	11,768	12,298
Interest expense	0	1,262	2,106	5,326	10,280	17,148
Other income (expense)	82	(1,249)	(979)	2,451	—	—
Income tax expense (benefit)	0	—	—	—	—	—
Net income (loss)	(9,474)	(29,605)	(40,370)	(63,779)	(111,779)	(177,042)
Earnings per share, basic USD per share	—	(2.21)	(2.64)	(2.69)	(2.83)	(3.79)
Earnings per share, diluted USD per share	—	—	(2.64)	(2.69)	(2.83)	(3.79)
Weighted average shares, basic thousands of shares	—	13,383	15,419	23,679	39,449	46,758
Weighted average shares, diluted thousands of shares	—	—	15,419	23,679	39,449	46,758

Fiscal years (CELC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	11,638	84,286	24,572	30,663	22,515	165,703
Short-term investments	—	—	144,016	149,920	212,589	275,794
Total current assets	12,167	85,352	175,191	190,591	244,571	465,659
Property and equipment, net	559	312	260	229	337	499
Right-of-use asset	231	242	246	400	216	51
Total assets	12,957	85,906	175,697	191,219	245,123	466,558
Accounts payable	217	1,507	2,627	5,077	9,366	6,407
Accrued liabilities	775	803	4,060	8,927	22,185	—
Total current liabilities	1,185	2,506	6,882	14,189	31,723	44,152
Lease liability, non-current	61	62	61	226	54	—
Total liabilities	1,254	17,196	41,926	51,450	129,504	366,003
Accumulated deficit	(26,322)	(55,927)	(96,297)	(160,076)	(271,855)	(448,897)
Total stockholders' equity	11,702	68,710	133,771	139,769	115,619	100,555
Total liabilities and equity	12,957	85,906	175,697	191,219	245,123	466,558
Common shares outstanding (cover page) thousands of shares	10,304	14,920	21,689	30,453	37,839	48,337

Fiscal years (CELC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(9,474)	(29,605)	(40,370)	(63,779)	(111,779)	(177,042)
Stock-based compensation	1,764	2,610	4,638	4,901	6,988	21,383
Net cash from operating activities	(7,146)	(20,312)	(36,008)	(53,812)	(83,467)	(153,280)
Purchases of property and equipment	(89)	82	159	98	250	249
Net cash from investing activities	(89)	(81)	(144,032)	(5,008)	(63,069)	(64,084)
Net cash from financing activities	138	93,042	120,325	64,912	138,388	360,552

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Celcuity	182,049	not reported	(55,426)*	48.9M	13.6 quarters	Q2 FY26 10-QJun 30, 2026
Fortrea Holdings	220,600	691,500	60,800*	96.5M	—	Q3 FY26 10-QSep 30, 2026
Castle Biosciences	62,116	103,546	15,201*	30.5M	—	Q2 FY26 10-QJun 30, 2026
Personalis	98,271	25,596	(27,072)*	108.4M	6.7 quarters	Q3 FY26 10-QSep 30, 2026
Fulgent Genetics	26,305	85,389	(23,758)*	27.5M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
CareDx	250,480	139,362	12,718*	52.5M	—	Q3 FY26 10-QSep 30, 2026
Exagen	24,588	19,941	3,988*	24.2M	—	Q2 FY26 10-QJun 30, 2026
Veracyte	299,521	150,321	45,826*	80.4M	—	Q2 FY26 10-QJun 30, 2026
GRAIL	55,645	44,687	(80,730)*	44.7M	0.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.